$306.28
-2.09 (-0.678%)
At Close: Aug 04, 2026
Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised
09:46am, Wednesday, 01'st May 2024
Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora (COR) Q2 Earnings Top Estimates
08:41am, Wednesday, 01'st May 2024
Cencora (COR) came out with quarterly earnings of $3.80 per share, beating the Zacks Consensus Estimate of $3.65 per share. This compares to earnings of $3.50 per share a year ago.
Cencora beats profit estimates on strong demand for costly specialty drugs
07:43am, Wednesday, 01'st May 2024
Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.
Cencora Reports Fiscal 2024 Second Quarter Results
06:30am, Wednesday, 01'st May 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 bil
Cencora (COR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:21am, Friday, 26'th Apr 2024
Beyond analysts' top -and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
3 High-Quality Stocks That Will Never Put You in the Red
06:24am, Tuesday, 23'rd Apr 2024
Every portfolio needs a solid foundation of high-quality stocks that can provide steady returns through all market environments. While I often discuss more speculative growth and penny stock plays in
Here's Why Cencora (COR) is a Strong Value Stock
10:46am, Monday, 15'th Apr 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cencora (COR) is a Strong Growth Stock
10:50am, Friday, 12'th Apr 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
08:30am, Friday, 05'th Apr 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening
Cencora, Inc. (COR) Soars to 52-Week High, Time to Cash Out?
10:16am, Thursday, 04'th Apr 2024
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Cencora (COR) is a Strong Value Stock
10:47am, Friday, 29'th Mar 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
10:51am, Wednesday, 27'th Mar 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Broker-Loved Stocks That Hold Promise Despite Volatility
09:46am, Wednesday, 27'th Mar 2024
We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.
Reasons to Add Cencora (COR) Stock in Your Portfolio Now
08:21am, Wednesday, 27'th Mar 2024
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora Remains Chronically Undervalued, With Material Growth Potential
09:11am, Monday, 25'th Mar 2024
Cencora, formerly known as AmerisourceBergen, has achieved a 14.97% YoY increase in total revenue, a 25.38% increase in net income, and a 27.84% increase in free cash flow. The company aims to become
Sign In
Buy COR